Clinical Trial Update: First in Human Study to Assess Safety of VIS649 in Healthy Subjects [Phase 1]

View source ↗

Summary

First-in-human Phase 1 study to assess the safety of VIS649 in healthy subjects has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunoglobulin Nephropathy

Drugs mentioned

• VIS649

Snippet

Sponsor: Visterra, Inc. | Conditions: Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy | Phase 1 | Status: COMPLETED | Results posted: 2025-03-20